Cardiol Therapeutics nears full enrollment for Phase III MAVERIC trial of CardiolRx in recurrent pericarditis
CRDL•Phase III MAVERIC trial nears full enrollment
- Cardiol Therapeutics plans to complete enrollment in its pivotal Phase III MAVERIC trial testing CardiolRx for reducing the risk of recurrent pericarditis.
- The strategy centers on using the newly published Phase II evidence base to support the Phase III program design and execution.
- Management is positioning CardiolRx as a potential non-immunosuppressive option for patients with recurrent disease.
